John P. Kenny - 31 Jan 2023 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC (VIVO)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ F. Mark Reuter, as Attorney-in-fact for John P. Kenny
Issuer symbol: VIVO
Transactions as of: 31 Jan 2023
Net transactions value: -$4,128,848
Form type: 4
Filing time: 31 Jan 2023, 13:12:52 UTC
Previous filing: 08 Nov 2022
Next filing: 24 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIVO	Common Stock	Award		+47,060	+21%		267,651	31 Jan 2023	Direct	F1
transaction	VIVO	Common Stock	Disposed to Issuer		-267,651	-100%		0	31 Jan 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	$1,578,332	-66,039	-100%	$23.90	0	31 Jan 2023	Common Stock	66,039	$10.10	Direct	F3
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	$1,296,463	-83,535	-100%	$15.52	0	31 Jan 2023	Common Stock	83,535	$18.48	Direct	F4
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	$1,254,053	-82,940	-100%	$15.12	0	31 Jan 2023	Common Stock	82,940	$18.88	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John P. Kenny is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below).
F2	The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F3	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.